David Amsellem
Stock Analyst at Piper Sandler
(4.79)
# 119
Out of 5,049 analysts
158
Total ratings
65.08%
Success rate
23.49%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Reiterates: Overweight | $284 → $289 | $217.94 | +32.61% | 2 | Nov 5, 2025 | |
| INDV Indivior | Reiterates: Overweight | $27 → $41 | $31.66 | +29.50% | 6 | Oct 31, 2025 | |
| AMRX Amneal Pharmaceuticals | Reiterates: Overweight | $11 → $13 | $11.65 | +11.64% | 5 | Oct 31, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $175 → $179 | $153.43 | +16.67% | 12 | Oct 29, 2025 | |
| ALKS Alkermes | Reiterates: Overweight | $38 → $45 | $32.07 | +40.32% | 8 | Oct 23, 2025 | |
| SUPN Supernus Pharmaceuticals | Upgrades: Overweight | $40 → $65 | $46.12 | +40.94% | 17 | Oct 9, 2025 | |
| AMGN Amgen | Maintains: Overweight | $328 → $342 | $316.67 | +8.00% | 5 | Aug 25, 2025 | |
| BIIB Biogen | Maintains: Neutral | $115 → $118 | $154.60 | -23.67% | 2 | Aug 14, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $30 → $25 | $25.18 | -0.71% | 9 | Aug 8, 2025 | |
| CORT Corcept Therapeutics | Maintains: Overweight | $131 → $121 | $74.71 | +61.96% | 8 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $18 | $6.52 | +176.29% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 → $37 | $39.48 | -6.28% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $176 → $147 | $130.93 | +12.27% | 14 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $65 | $46.15 | +40.85% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3 → $4 | $8.03 | -50.19% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $10 | $10.31 | -3.01% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $30 | $24.19 | +24.02% | 10 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $13 | $18.92 | -31.27% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $92.92 | -26.82% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $6.74 | -55.49% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $21.64 | +94.09% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $6.21 | +61.03% | 1 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $1.99 | +957.93% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $136.53 | -17.23% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $30.45 | +37.93% | 3 | Oct 16, 2023 |
AbbVie
Nov 5, 2025
Reiterates: Overweight
Price Target: $284 → $289
Current: $217.94
Upside: +32.61%
Indivior
Oct 31, 2025
Reiterates: Overweight
Price Target: $27 → $41
Current: $31.66
Upside: +29.50%
Amneal Pharmaceuticals
Oct 31, 2025
Reiterates: Overweight
Price Target: $11 → $13
Current: $11.65
Upside: +11.64%
Neurocrine Biosciences
Oct 29, 2025
Maintains: Overweight
Price Target: $175 → $179
Current: $153.43
Upside: +16.67%
Alkermes
Oct 23, 2025
Reiterates: Overweight
Price Target: $38 → $45
Current: $32.07
Upside: +40.32%
Supernus Pharmaceuticals
Oct 9, 2025
Upgrades: Overweight
Price Target: $40 → $65
Current: $46.12
Upside: +40.94%
Amgen
Aug 25, 2025
Maintains: Overweight
Price Target: $328 → $342
Current: $316.67
Upside: +8.00%
Biogen
Aug 14, 2025
Maintains: Neutral
Price Target: $115 → $118
Current: $154.60
Upside: -23.67%
Amphastar Pharmaceuticals
Aug 8, 2025
Maintains: Neutral
Price Target: $30 → $25
Current: $25.18
Upside: -0.71%
Corcept Therapeutics
Aug 1, 2025
Maintains: Overweight
Price Target: $131 → $121
Current: $74.71
Upside: +61.96%
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $6.52
Upside: +176.29%
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $39.48
Upside: -6.28%
May 7, 2025
Reiterates: Overweight
Price Target: $176 → $147
Current: $130.93
Upside: +12.27%
Apr 22, 2025
Initiates: Overweight
Price Target: $65
Current: $46.15
Upside: +40.85%
Mar 7, 2025
Reiterates: Neutral
Price Target: $3 → $4
Current: $8.03
Upside: -50.19%
Mar 5, 2025
Reiterates: Neutral
Price Target: $14 → $10
Current: $10.31
Upside: -3.01%
Jan 17, 2025
Maintains: Overweight
Price Target: $23 → $30
Current: $24.19
Upside: +24.02%
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $18.92
Upside: -31.27%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $92.92
Upside: -26.82%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $6.74
Upside: -55.49%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $21.64
Upside: +94.09%
Apr 11, 2024
Initiates: Overweight
Price Target: $10
Current: $6.21
Upside: +61.03%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $1.99
Upside: +957.93%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $136.53
Upside: -17.23%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $30.45
Upside: +37.93%